ARVO 2018: Dr. Steve Rose Reports on CRISPR/Cas9 for Inherited Retinal Diseases
Eye On the Cure Research News
FFB’s own Dr. Steve Rose, chief scientific officer, reviews our commitment to funding and exploring CRISPR/Cas9 gene editing for inherited retinal disease.
FFB's own Dr. Steve Rose, chief scientific officer, reviews our commitment to funding and exploring CRISPR/Cas9 gene editing for inherited retinal disease in the video below. FFB currently funds CRISPR/Cas9 projects at four institutions:
- Johns Hopkins University (retinitis pigmentosa caused by the P23H mutation in RHO)
- Columbia University (RP caused by the D190N mutation in RHO)
- Massachusetts Eye and Ear Infirmary (RP caused by a mutation in RP1)
- UCLA (Usher syndrome 1B caused by a mutation in MYO7A)
Want to learn more about the benefits of CRISPR/Cas9? Check out: A Cut-and-Paste Approach to Fixing Retinal-Disease Genes
